Sanam Loghavi

This study identifies BRAF mutations in AML, showing poor outcomes and unique co-mutation patterns, suggesting potential targeted therapies.

This study characterizes myeloid sarcoma through multi-omic profiling, identifies RAS pathway activation as a hallmark, and shows RAS inhibition reduces tumor burden in mouse models.

This study shows that resistant clones are rapidly selected in hematopoietic cell compartments with leukemic stem cell potential before relapse in patients treated with ivosidenib combination therapy.

This study shows MDS hematopoietic stem cells reprogram their differentiation state to bypass venetoclax sensitivity through genetic mutations and transcriptional changes.

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

This study shows that IL-1B-mediated inflammation drives ineffective erythropoiesis in early-stage MDS and that canakinumab can reduce transfusion dependence in patients with DNMT3A and TET2 mutations.

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.